南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

软骨发育不全患者来源iPSC的CRISPR-Cas9靶向基因校正与功能恢复

Targeted gene correction and functional recovery in achondroplasia patient-derived iPSCs

Zou Huan, Guan Mingfeng, Li Yundong, Luo Fang, Wang Wenyuan, Qin Yiren

Journal:Stem Cell Research & Therapy

IF:6.83

DOI:10.1186/s13287-021-02555-8

PMID:34454631

Published:2021-08-28

research field:肿瘤学免疫学

Abstract

Background Achondroplasia (ACH) is the most common genetic form of dwarfism and belongs to dominant monogenic disorder caused by a gain-of-function point mutation in the transmembrane region of FGFR3. There are no effective treatments for ACH. Stem cells and gene-editing technology provide us with effective methods and ideas for ACH research and treatment.Methods We generated non-integrated iPSCs from an ACH girl’s skin and an ACH boy’s urine by Sendai virus. The mutation of ACH iPSCs was precisely corrected by CRISPR-Cas9.Results Chondrogenic differentiation ability of ACH iPSCs was confined compared with that of healthy iPSCs. Chondrogenic differentiation ability of corrected ACH iPSCs could be restored. These corrected iPSCs displayed pluripotency, maintained normal karyotype, and demonstrated none of off-target indels.Conclusion sThis study may provide an important theoretical and experimental basis for the ACH research and treatment.

本文使用的Yeasen产品

购物车
客服
转染试用